Re your second para oldtimer, I think it’s unlikely the FDA meets with all companies post-trial. After all, what would be the point if, as often is the case, a trial is unequivocally negative? In the absence of any safety issue, I would imagine a post-trial meeting is held only when:
1. The endpoint results have raised the possibility of marketing approval for one or more conditions;
2. The results for an important endpoint just missed statistical significance and the company wants to reach agreement with the FDA on the way forward.